SCHEMBL17898313

SCHEMBL17898313

CC(C)COc1ccc(Oc2nc(O)c3ccncc3n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 15/20 0.52
▸ KDM4E B2RXH2 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ S1PR1 P21453 1/20 0.39
▸ KDM4A O75164 1/20 0.38
▸ KDM5C P41229 1/20 0.38
▸ KDM4D Q6B0I6 1/20 0.38
▸ AAK1 Q2M2I8 2/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ LATS1 O95835 1/20 0.35
▸ LATS2 Q9NRM7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17602219 0.92 KDM4C (0.63) KDM4C
SCHEMBL17503666 0.87 KDM4C (0.42) KDM4CKDM4ES1PR1KDM4AKDM5C
SCHEMBL17503677 0.82 ALDH1A1 (0.50) KDM4CKDM4EALDH1A1LMNAKDM4A
SCHEMBL17898299 0.81 KDM4C (0.46) KDM4C
SCHEMBL19159046 0.80 KDM4C (0.44) KDM4C
SCHEMBL16096164 0.79 KDM4C (0.53) KDM4CKDM4EKDM4AKDM5CKDM4D
SCHEMBL16095235 0.79 HTT (0.40) KDM4CKDM4ELMNAKDM4AKDM5C
SCHEMBL17602192 0.79 KDM4C (0.63) KDM4C
SCHEMBL17503825 0.79 KDM4C (0.51) KDM4CKDM4E
SCHEMBL19159058 0.79 KDM4C (0.41) KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3430008-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-05-18 — — EP disclosed
US-10208039-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-02-19 — — US disclosed
US-10202381-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-02-12 — — US disclosed
US-10030017-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-24 — — US disclosed
US-10030017-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-24 — — US disclosed
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-14 — — US disclosed
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-14 — — US disclosed
WO-2017161012-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-09-21 — — WO disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A KDM4C 9/4885KDM4E 17/4885NPC1 4609/4885
US-10030017-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885KDM4E 17/4885NPC1 4609/4885
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A KDM4C 9/4885KDM4E 17/4885NPC1 4609/4885
US-10202381-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885KDM4E 17/4885NPC1 4609/4885
US-10208039-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885KDM4E 17/4885NPC1 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback